# Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC

> **NCT06752382** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 58 (estimated)

## Conditions studied

- Locally Advanced Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Experimental drug

## Key facts

- **NCT ID:** NCT06752382
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06752382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06752382, "Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06752382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*